Enterome
PrivateLast Round
VC Round
Jun 12, 2025
Total Funding Raised
$179.97M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Enterome operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a VC Round in June 2025.
Enterome is a biotechnology company that develops immunomodulatory drugs and therapeutic vaccines for cancer and immune-related diseases based on its proprietary gut microbiome-derived Mimicry platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enterome Comparables
Compare Enterome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exeliom Biosciences | 78% | |
| MaaT Pharma | 78% | |
| Vedanta Biosciences | 74% |
For institutional investors. Book with your work email.
Enterome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jun 12, 2025 | ||||
| Early Funding | Aug 25, 2023 | ||||
| Series E | Jun 25, 2020 | ||||
| Series D | Jan 4, 2018 | ||||
| Debt | Jan 4, 2018 | ||||
Series C | Apr 20, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Enterome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Series D, Series B, Series A, Series C |
| SymBiosis Capital Management | VC Round, Series E |
| Lundbeckfonden BioCapital | VC Round |
| INRAE Transfert | Seed, Series C |
| European Investment Bank Group | Debt |
| Primo Capital | VC Round |
| Natixis Corporate & Investment Banking | VC Round, Series D, Series B, Series E, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 99% MoM.
- Jan 29, 2026
Mehrdad Mobasher, M.D., M.P.H. joins the Board of Directors.
For institutional investors. Book with your work email.
Enterome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Enterome's valuation, stock price, and market status.
Is Enterome a public or private company?
Enterome is a private company.
What is the current stock price of Enterome?
Enterome is a private company, so its shares have no public market price. Caplight tracks Enterome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enterome worth (valuation)?
Valuation information for Enterome is not publicly available.
Can I buy Enterome stock?
Enterome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enterome's last funding round?
Enterome's most recent funding round was VC Round on June 12, 2025.
Who are the main investors in Enterome?
Key investors in Enterome include Lundbeck Foundation, Institute for Follicular Lymphoma Innovation, Lundbeckfond Ventures, Seventure Partners, Principia SGR.
Will Enterome IPO soon?
No public IPO plans have been announced for Enterome.
How can I track Enterome secondary market activity?
Caplight tracks bids, offers, and trades in Enterome's shares on secondary markets.